Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Camrelizumab combined with chemotherapy and apatinib as first-line treatment for extensive-stage small cell lung cancer
ChiCTR2000035599Phase 4Not yet recruiting
- Sponsor
- Harbin Medical University Cancer Hospital
- Start
- Sep 2020
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules, Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of camrelizumab and Rivoceranib in small cell lung cancer (SCLC), sponsored by Harbin Medical University Cancer Hospital. Primary endpoint: 6-month progression-free survival rate. Planned start Sep 2020; status: not yet recruiting.
02
Drugs
camrelizumabRivoceranib
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on ChiCTR2000035599.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2000035599.